Literature DB >> 12057992

In vivo imaging of proteolytic activity in atherosclerosis.

Jiqiu Chen1, Ching-Hsuan Tung, Umar Mahmood, Vasilis Ntziachristos, Robert Gyurko, Mark C Fishman, Paul L Huang, Ralph Weissleder.   

Abstract

BACKGROUND: Atherosclerotic plaque rupture, the most important cause of acute cardiovascular incidents, has been strongly associated with vascular inflammation. On the basis of the hypothesis that the inflammatory response and proteolysis lead to plaque rupture, we have examined the role of cathepsin B as a model proteolytic enzyme. METHODS AND
RESULTS: Using western-type diet-fed apoE and apoE/endothelial NO synthase double knockout mice as models of atherosclerosis, we show (1) that cathepsin B is upregulated in atherosclerotic lesions characterized by high degrees of inflammation compared with normal aorta or silent lesions, (2) that intravenously injectable novel cathepsin B imaging beacons are highly activated within active atherosclerotic lesions and colocalize with cathepsin B immunoreactivity, and (3) that cathepsin B activity in atherosclerotic lesions can be imaged in whole animals by using a novel near-infrared tomographic imaging system.
CONCLUSIONS: These studies indicate that cathepsin B, and potentially other proteases, may serve as a biomarker for vulnerable plaques when probed with beacons. The tomographic in vivo imaging method as well as catheter-based optical sensing methods could be readily adapted to screening and potentially to the molecular profiling of a number of proteases in vulnerable plaque in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12057992     DOI: 10.1161/01.cir.0000017860.20619.23

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  111 in total

1.  Levels of cathepsins in acute myocardial infarction.

Authors:  Kavita K Shalia; Manoj R Mashru; Vinod K Shah; Surendra L Soneji; Satchidanand Payannavar
Journal:  Indian Heart J       Date:  2012 May-Jun

Review 2.  Magnetic resonance imaging of coronary atherosclerosis.

Authors:  Zahi A Fayad; Robin P Choudhury; Valentin Fuster
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

3.  Second Annual Mario S. Verani, MD, Memorial Lecture: Nuclear cardiology, the next 10 years.

Authors:  Barry L Zaret
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

Review 4.  Vulnerable plaque imaging-current techniques.

Authors:  K Chad Hilty; Daniel H Steinberg
Journal:  J Cardiovasc Transl Res       Date:  2009-01-14       Impact factor: 4.132

Review 5.  Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques.

Authors:  Shann S Yu; Ryan A Ortega; Brendan W Reagan; John A McPherson; Hak-Joon Sung; Todd D Giorgio
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-08-10

Review 6.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

7.  Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction.

Authors:  Jiqiu Chen; Ching-Hsuan Tung; Jennifer R Allport; Si Chen; Ralph Weissleder; Paul L Huang
Journal:  Circulation       Date:  2005-04-04       Impact factor: 29.690

Review 8.  Molecular imaging in cardiovascular disease: Which methods, which diseases?

Authors:  Jonathan R Lindner; Albert Sinusas
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

9.  Near-infrared fluorophores containing benzo[c]heterocycle subunits.

Authors:  Scott T Meek; Evgueni E Nesterov; Timothy M Swager
Journal:  Org Lett       Date:  2008-06-19       Impact factor: 6.005

10.  Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis.

Authors:  Farouc A Jaffer; Claudio Vinegoni; Michael C John; Elena Aikawa; Herman K Gold; Aloke V Finn; Vasilis Ntziachristos; Peter Libby; Ralph Weissleder
Journal:  Circulation       Date:  2008-10-13       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.